Martin Steegmaier
Chief Scientific Officer Molecular Partners
Martin Steegmaier, Ph.D., serves as Chief Scientific Officer and member of the Management Board at Molecular Partners. A seasoned R&D leader with extensive experience in oncology, biologics, and antibody engineering, he has held senior scientific leadership positions across both biotechnology and pharmaceutical companies. Before joining Molecular Partners, he was Chief Scientific Officer at SOTIO Biotech, leading the development of a diversified oncology pipeline. Earlier in his career, Martin served as Head of Research at MorphoSys and held senior leadership roles at Roche and Boehringer Ingelheim, where he contributed to the discovery and development of innovative therapeutic approaches across oncology and multiple disease areas.
Seminars
- Evaluating the biological, translational and clinical characteristics that separate promising radiopharmaceutical targets from those unlikely to succeed in development
- Debating how developers should balance target expression, tumour selectivity, internalisation, accessibility and heterogeneity when prioritising targets for investment
- Comparing the opportunities and limitations of established and emerging targets including DLL3, FAP, CAIX and others to determine where the next wave of radiopharmaceutical innovation will emerge
- Presenting imaging and dosimetry insights from MP0712, a DLL3-targeted Pb-212 Radio-DARPin Therapeutic currently in Phase I development
- Exploring how half-life extended Radio-DARPins are designed to overcome the limitations of conventional peptide-based radiopharmaceutical approaches for challenging targets
- Sharing key learnings from advancing a novel targeted alpha therapy approach across clinical and preclinical development programmes
